['esophageal neoplasms']
['s1', 's-1', 'irinotecan']

        Inclusion Criteria:

          -  Histologically proven esophageal squamous cell carcinoma;

          -  18 ≤ age ≤ 70;

          -  ECOG 0-2;

          -  Previously Treated with platinum or paclitaxel based regimen;

          -  Uni-dimensionally measurable disease (CT or MRI as per RECIST);

          -  Patients should have a projected life expectancy of at least 3 months;

          -  Completion of baseline quality of life questionnaire

          -  Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul,
             haemoglobin ≥ 10g/dl);

          -  Adequate renal functions(serum creatinine ≤ 1.5mg/dl)

          -  liver functions (serum bilirubin ≤ 1.5UNL, AST/ALT ≤ 3 times(normal value)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy with 5-FU or irinotecan after recurrence or metastasis;

          -  adjuvant chemotherapy with 5-FU-based chemotherapy within 6 months prior to the start
             of study treatment;

          -  Active infection requiring antibiotics

          -  Pregnant, lactating women

          -  Psychiatric illness, epileptic disorders

          -  Concurrent systemic illness not appropriate for chemotherapy

          -  History of other malignancy within 5 years except for non-melanoma skin cancer, cervix
             in situ carcinoma
      